Roche Q3 sales rise 10 percent
China Daily | Updated: 2009-10-16 08:04
|
Roche has been trading at a premium to European rivals GlaxoSmithKline, Sanofi-Aventis, Novartis and AstraZeneca thanks to its strong position in cancer and biotech drugs. Bloomberg News |
ZURICH: Roche's third-quarter sales rose 10 percent to 12.4 billion Swiss francs ($12.2 billion), helped by its cancer drugs and increased demand for flu medicine Tamiflu due to the H1N1 pandemic.
Photo
